Neuroprotection and Remyelination after Autoimmune Demyelination in Mice that Inducibly Overexpress CXCL1

Kakuri M. Omari,* Sarah E. Lutz,* Laura Santambrogio,* Sergio A. Lira,† and Cedric S. Raine*‡§

From the Departments of Pathology (Neuropathology),* Neurology,‡ and Neuroscience,§ Albert Einstein College of Medicine, Bronx; and the Departments of Medicine,† Immunology Institute, Mount Sinai School of Medicine, New York, New York

In rodents, the chemokine CXCL1 both induces the proliferation and inhibits the migration of oligodendrocyte precursor cells. We previously reported that in multiple sclerosis, the same chemokine is expressed by hypertrophic astrocytes, which associate with oligodendrocytes that express the receptor CXCR2. To investigate whether chemokines influence repair after autoimmune demyelination, we generated GFAP-rtTA × β-Gal-TRE-CXCL1 double-transgenic (Tg) mice that inducibly overexpress CXCL1 under the control of the astrocyte-specific gene, glial fibrillary acidic protein. Experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis, was induced in these animals (and controls) by the subcutaneous injection of myelin oligodendrocyte glycoprotein, and after disease onset, CXCL1 production was initiated by the intraperitoneal injection of doxycycline. Double-Tg animals displayed a milder course of disease compared with both single (CXCL1 or glial fibrillary acidic protein)-Tg and wild-type controls. Pathologies were similar in all groups during the acute stage of disease. During the chronic disease phase, both inflammation and demyelination were diminished in double-Tg mice and Wallerian degeneration was markedly decreased. Remyelination was strikingly more prominent in double-Tg mice, together with an apparent increased number of oligodendrocytes. Moreover, cell proliferation, indicated by BrdU incorporation within the central nervous system, was more widespread in the white matter of double-Tg animals. These findings suggest a neuroprotective role for CXCL1 during the course of autoimmune demyelination. (Am J Pathol 2009, 174:164–176; DOI: 10.2353/ajpath.2009.080350)
remyelination (albeit limited in extent) has also been reported to take place during the active stage of the disease. The presence of oligodendrocyte precursor cells in normal and MS white matter is in accord with the generation of new oligodendrocytes. Recent studies report that remyelination can be extensive in MS patients with long-standing disease.

In addition to their prime function as myelinating cells, oligodendrocytes are currently considered a more dynamic cell type, bearing (in humans) receptors normally associated with the immune system, suggesting that these cells might also be capable of responding to inflammatory signals. In the rat, oligodendrocytes have been found to express CXCR1 and CXCR2 and to show proliferative and migratory responses to the chemokine, CCL1. It has also been reported that CXCR4, interacting with the ligand CXCL12, influences neuronal and oligodendrocyte precursor survival and migration. More recently, the chemokine, CCL11, has been shown to increase proliferation, inhibit migration and augment differentiation of primary rat oligodendrocyte precursor cells via CCR3. Astrocytes are a major source of chemokines within the CNS, and this cell type might function in the regulation of oligodendrocyte behavior in MS.

To test the effects of astrocyte-produced CXCL1 on oligodendrocytes (known to express CXCR2), we generated a novel double-transgenic (Tg) mouse (GFAP-rtTA) × β-Gal-TRE-CXCL1), which was then sensitized for EAE. Using this model, we were able to induce the production of CXCL1 by astrocytes in situ, after administration of doxycycline. Our findings demonstrate that double-Tg animals overexpressing CXCL1 displayed a milder form of EAE that was associated with reduced pathology [Wallerian degeneration (WD), demyelination] and more prominent remyelination. These findings suggest that CXCL1/CXCR2-mediated signals play a neuroprotective role during the course of CNS autoimmune demyelination.

Materials and Methods

Generation of GFAP-rtTA × β-Gal-TRE-CXCL1 Double-Tg Animals

We generated double-Tg mice that overexpress CXCL1 under the control of the promoter of the astrocyte-specific gene, glial fibrillary acidic protein (GFAP) on a C57BL/6 background. This was achieved by mating two strains of mice: mouse strain 1, containing the pTetOn-GFAP construct, which induces the expression of the rtTA-VF16 (reverse tetracycline-controlled transactivator fusion protein) under the control of the GFAP promoter, and mouse strain 2, carrying the pTRE2-N51/CXCL1 construct, of which the TRE (tetracycline response element) promoter is made up of Tet operator (tetO) sequence concatamers fused to a minimal CMV promoter. The F1 cross between these two transgenic animals expresses rtTA-VF16 in GFAP-positive cells. This in turn, and only in the presence of tetracycline or its derivative doxycycline, drives the expression of the CXCL1 and β-gal gene products in astrocytes (Figure 1). Tail DNA isolated from littermates was analyzed by polymerase chain reaction (PCR) for the presence of the transgenes using primers that amplify a 500-bp segment of the GFAP-rtTA/VF16 construct (GFAP forward: 5'-GCTCCACTCCAATCCAGGCTATTCAA-3'; GFAP reverse: 5'-TAAAGGGCAAAAA GTGAGTATGGTG-3'), and a 190-bp fragment of the TRE-N51/CXCL1 construct (CXCL1 forward: 5'-CTGGGATTCACCTCAGGCAAC-3'; CXCL1 reverse: 5'-GGGGACACCTTTAGGATCT-3').

Tail DNA template (50 ng) was amplified in 25 μl of PCR mixtures containing 12.5 pmol of each primer added to PuReTaq Ready-To-Go PCR beads (GE Health Care Bio-Sciences Corp., Piscataway, NJ). DNA amplification was performed as follows: denaturation step at 94°C for 5 minutes, annealing step at 55°C for 1 minute, an extension step at 72°C for 3 minutes, followed by 39 cycles of 94°C denaturation for 30 seconds, 55°C annealing for 30 seconds, 72°C elongation for 45 seconds, and a final elongation step at 72°C for 7 minutes. A 10-μl sample of each PCR reaction was analyzed by electrophoresis on 2% agarose gels to distinguish double- and single-Tg animals by the presence or absence of the CXCL1 and GFAP DNA fragments (Figure 1).

Induction of CXCL1 in Double-Tg Mice

To determine the ability to induce CXCL1 production in the novel tetracycline-inducible Tg system, double-Tg animals at 8 to 12 weeks of age received intraperitoneal...
injections of 500 µg of doxycycline (Sigma, St. Louis, MO)²¹ for a period of 7 days (four injections). Animals were sacrificed 2 to 14 days after injection, and expression of CXCL1 was confirmed by immunohistochemistry using antibodies against CXCL1 and β-gal, as described below. Mice were also monitored for neurological signs during the 14-day period and analyzed for infiltration and demyelination to assess the global effects of regulated CXCL1 overexpression in the adult CNS. CXCL1 single-Tg and wild-type littermate mice were also treated with doxycycline for 7 days, and double-Tg animals receiving no doxycycline served as controls. A total of four animals were analyzed at each time point and processed for histopathology and immunohistochemistry analysis.

**Myelin Oligodendrocyte Glycoprotein (MOG)-induced EAE**

The new inducible Tg model (described above) was used to test the effects of regulated overexpression of CXCL1 during the course of CNS inflammation. Double-Tg mice, 8 to 12 weeks of age, were sensitized for actively induced EAE by subcutaneous injection (two dorsal flank sites) of 200 to 400 µg of encephalitogenic MOG₃₅-₅₅ peptide in incomplete Freund’s adjuvant supplemented with *Mycobacterium tuberculosis* followed by 500 ng of pertussis toxin intraperitoneally on days 0 and 2 after injection.²⁵ At initial signs of disease, doxycycline (500 µg) was injected into the peritoneal cavity throughout a period of 7 days (four injections) to cause overproduction of CXCL1 by astrocytes, and then removed (at which point CXCL1 production by astrocytes ceased). Animals were observed for up to 60 days after injection and scored on a clinical scale of 0 to 5 (grade 0, no abnormalities; grade 1, weak tail; grade 2, limp tail and weakness of hind-limbs; grade 3, hind-limb paraparesis; grade 4, tetraplegia; grade 5, moribund or death). For controls, CXCL1 and GFAP single-Tg, and wild-type littermates were similarly sensitized for EAE and treated with doxycycline. A total of 25 double-Tg, 23 single-Tg, and 10 wild-type animals were analyzed in EAE experiments.

**Western Blotting**

Western blotting was conducted to semiquantitate β-gal protein levels in animals after doxycycline treatment. Frozen spinal cord and brain tissue from each experimental group was homogenized on ice in lysis buffer and protein concentration determined using the Bio-Rad BCA assay (Bio-Rad, Hercules, CA). Protein samples (25 to 100 µg) were loaded in reducing sodium dodecyl sulfate buffer (1:5), separated on 10 to 15% sodium dodecyl sulfate-polyacrylamide gels (Mini-Protean, Bio-Rad), and transferred onto polyvinylidene difluoride membranes for 2 hours (Millipore, Bedford, MA). After blocking in 5% fat-free milk powder/PBS/0.05% Tween 20 (pH 7.4), membranes were incubated in diluted anti-β-gal antibody for 2 hours at room temperature. After washing and incubation in horseradish peroxidase-coupled secondary antibody (Vector Laboratories), immunoreactive bands for β-gal were visualized by enhanced chemiluminescence (SuperSignal West Pico chemiluminescent substrate; Pierce, 305 La Jolla, CA).
BrdU Proliferation Assay

CXCL1-generated signals have been reported to influence oligodendroglial proliferation. To assess this in double-Tg mice, 50 mg/kg of 5-bromo-2’-deoxyuridine (BrdU, Sigma), a pyrimidine analog of thymidine that is selectively incorporated into cell DNA at the S phase of the cell cycle, was injected into animals at the same time as doxycycline. This allowed it to be integrated into the DNA of cells undergoing division after induction of CXCL1 production by astrocytes. Proliferation, indicated by BrdU incorporation, was detected using an anti-BrdU antibody (LabVision, Fremont, CA). After fixation, frozen sections were pretreated with 2 N hydrochloric acid to denature the DNA, rinsed thoroughly in PBS after prewashing in 0.1 mol/L sodium tetraborate (Na₂B₄O₇·4·H₂O/borax), incubated with primary antibody, and developed by standard immunohistochemistry techniques, as described above.

Data Acquisition and Analysis

Digital images of tissue sections were acquired on a Zeiss Axioskop epifluorescent microscope (Carl Zeiss, Thornwood, NY). Data from EAE experiments were subjected to analysis of variance to determine differences between treatment groups. Where differences were found, Student-Newman-Keuls all pairwise multiple comparisons were conducted to analyze individual differences against control groups. The Student’s t-test was applied to histopathological data to determine differences within treatment groups. Data were analyzed using SigmaStat v2.03 and graphs were generated on SigmaPlot 8.0 (SPSS Science, Chicago, IL).

Results

Generation of GFAP-rtTA × β-Gal-TRE-CXCL1 Double-Tg Mice

Generation of GFAP-rtTA × β-Gal-TRE-CXCL1 double-Tg mice was achieved by crossing two strains of mice, one strain containing the pTetO/GFAP construct, and the second, a pTRE2-N51/CXCL1 construct (Figure 1, top). Both Tg constructs were potentially expressed in every cell in the resulting double-Tg animals but because the Tet sequence was linked to a GFAP promoter, regulation was only effective in astrocytes when the animal was given tetracycline, or its derivative, doxycycline. At this point, the Tet transcription product from the GFAP/Tet construct activated the Tet response element on the second transgene to up-regulate expression of CXCL1 within the CNS. Representative genotyping of littersmates is shown in Figure 1, bottom. Single-Tgs expressed the 500-bp DNA fragment indicating the presence of the GFAP transgene and the 190-bp band representing the CXCL1 gene, with double-Tg animals displaying both bands.

β-Gal Expression in Doxycycline-Treated Animals

β-Gal expression was analyzed in mice treated with doxycycline to confirm induced transgene expression in CNS tissue. Double-Tg animals and control mice received a total of four intraperitoneal injections of doxycycline (500 μg), administered every other day. Immunohistochemistry demonstrated an increase in β-gal up to 3 days after the last doxycycline injection (day 9), which appears to be decreasing by day 13 (Figure 2, A–C). In controls, weak β-gal reactivity was detected in CXCL1 single-Tg mice receiving the full compliment of injections (Figure 2D). Double-immunofluorescent staining confirmed expression of β-gal by astrocytes in Tg mice. More protein was detected in doxycycline-treated double-Tg mice (Figure 2E), compared with sterile PBS-treated double-Tg control mice (Figure 2F). At high magnification, the β-gal protein appeared to co-localize with the astrocytic marker, GFAP, in both treated and control animals (Figure 2, F, G, J, and K). CXCL1 expression was up-regulated in astrocytes and their processes in spinal cord tissue from doxycycline-treated normal double-Tg mice, but not in the CNS of double-Tg mice not receiving doxycycline (Figure 2, H and L).

Western blot analysis revealed a similar increase in β-gal protein starting 5 days after initiating doxycycline treatment, and up to a week after the last injection. Similar to immunohistochemistry results, low levels of β-gal protein were present in spinal cord tissue from control double-Tg animals not receiving doxycycline and in doxycycline-treated single-Tg mice (Figure 3A). In addition, levels of β-gal protein were analyzed in tissue samples from mice with MOG-induced EAE. Similar to disease-free animals, higher levels of β-gal were detected in spinal cord tissue from double-Tg mice after doxycycline injections, compared with tissue samples from single-Tg animals or wild-type controls (Figure 3B). Together, these results demonstrate specific induction of the β-gal and CXCL1 genes and suggested that CXCL1 overproduction was achieved in double-Tg mice.

EAE in Transgenic Mice

MOG-EAE was induced in double-Tg, and in control, single-Tg mice and wild-type, animals. At the onset of EAE, CXCL1 production by astrocytes was induced by injection of doxycycline. Single-Tg and wild-type animals developed moderate EAE (grade 3), whereas double-Tg animals displayed a milder course (grade 1 to 2) (Figure 4, A–C). Double-Tg mice recovered soon after the initial phase of EAE, by days 20 to 25 after injection, whereas the majority of control animals had more severe disease.
for the duration of the experiments (40 to 60 days). Differences in clinical EAE were statistically significant ($P < 0.05$) between double-Tg and control animals (wild-type and single-Tg), especially during the late acute phase of EAE. Introduction of the two transgenes had no significant effect on the induction of EAE.

Histopathology was quantitated blindly under code by two investigators (K.M.O. and C.S.R.). CNS tissue from different regions, derived from double-Tg and control mice with EAE, was scored on a scale of 0 to 5 for inflammation, demyelination, axonal pathology (WD), and remyelination. During the acute phase of EAE (15 to 20 days after injection), there were similar amounts of myelin loss, axonal pathology, and inflammation in double-Tg animals and controls. However, in the chronic phase (40 to 60 days after injection), inflammation, demyelination, and WD were reduced in double-Tg mice, compared with CXCL1 or GFAP single-Tg littermate controls (Figure 4, D and E). Relative to the degree of myelin and axonal pathology, remyelination was more pronounced in the
double-Tg group, a difference that was significant in the majority of regions of the CNS analyzed.

Immunohistochemistry revealed inflammatory cuffs containing T cells (CD4<sup>+</sup>/F4/80<sup>+</sup>) and macrophages/microglia, present in double-Tg, single-Tg, and wild-type animals during the late acute phase of EAE (15 and 20 days after injection). However, by 40 days after injection, few CD4<sup>+</sup> and F4/80<sup>+</sup> inflammatory cells were detected in lumbar anterior columns of double-Tg mice but were still prevalent in control animals (Figure 5, A–H). Immunostaining for neutrophils showed extensive infiltration in spinal cord sections from double-Tg mice at 15 days after injection compared with control single-Tg animals. However, by 20 days after injection, few neutrophils were present in both double-Tg and single-Tg mice (Figure 5, I–P). Because CXCL1 is a chemoattractant with the ability to influence neutrophil migration, these findings suggest that CXCL1 overproduction in mice with EAE resulted in increased neutrophil infiltration but numbers returned to control levels after doxycycline treatment ceased.

Reduced Demyelination and Axonal Damage in Double-Tg Mice with EAE

Histopathology revealed the presence of inflammation in spinal cord tissue from all groups (double-Tg, CXCL1 or GFAP single-Tg, and wild-type animals), at 15 days after injection, and demyelination and axonal pathology (WD) was also comparable in control mice (Figure 6, A–C). Samples from mice sacrificed after 40 days after injection showed less inflammation and WD in double-Tg animals, whereas single-Tg and wild-type mice still had extensive inflammation, demyelination, and axonal damage (Figure 6, D–F). This is in agreement with immunohistochemistry, which showed diminished inflammation in double-Tg animals compared with controls. During the chronic phase,
in both double-Tg and control spinal cord tissue, numerous axons appeared to be thinly myelinated, indicative of remyelination (Figure 6, D and E). Similarly, in the optic nerve, demyelination and inflammation were reduced in double-Tg animals (Figure 6G), compared with extensive damage, gliosis, and inflammation in single-Tg and wild-type mice (Figure 6, H and I). Interestingly, there appeared to be increased numbers of oligodendrocytes in double-Tg mice, suggestive of proliferation (Figure 6, D and G).

At the ultrastructural level, during the acute phase of EAE, inflammation and demyelination were prominent in spinal cord from double-Tg, single-Tg, and wild-type animals (Figure 7, A–C). During the chronic phase, remy-
elination was a major feature in double-Tg mice (Figure 7D). In contrast, although some remyelination was also evident in control animals, there was more ongoing de-myelination, WD, and inflammation in double-Tg mice (Figure 7, E and F). Similar to spinal cord tissue, remyelination associated with oligodendrocytes was present in optic nerve from double-Tg animals (Figure 7G). Persistent axonal degeneration and inflammation were also reduced in double-Tg animals (G), compared with the extensive damage, gliosis, and inflammation observed in single-Tg (H) and wt mice (I). As in the spinal cord, there appeared to be an increased number of oligodendrocytes in double-Tg mice (G, small arrows), suggestive of an oligodendroglial response. Inset in G highlights remyelination and oligodendrocytes in double-Tg mice; inset in H shows demyelination and WD; inset in I shows inflammation and demyelination. Scale bar 30 μm (A-I); 60 μm (for insets in A-I).

CXCL1/CXCR2 Expression and Cell Proliferation in Double-Tg Animals

CXCL1 has been shown to be involved in oligodendrocyte proliferation and positioning in rodents.47,48 CXCL1 expression was examined in CNS tissue from mice with EAE. CXCL1 immunoreactivity was apparent during the late acute phase (15 to 20 days after injection) in both double-Tg (Figure 8A) and single-Tg (Figure 8C) mice, in cells with the morphology of reactive astrocytes. CXCL1 was more intense and widespread in double-Tg animals, compared with single-Tg controls, suggesting induced overproduction after administration of doxycycline. Similar areas from mice with chronic EAE revealed diminished CXCL1 reactivity on astrocytes in both double-Tg (Figure 8B) and single-Tg animals (data not shown). These results confirmed our ability to induce overproduction of CXCL1 within the CNS.

Frozen sections from double-Tg mice were also stained for CXCR2, the receptor for CXCL1. Immunohistochemistry showed small, round cells with a typical oligodendroglial morphology expressing CXCR2 in spinal cord anterior columns. Some astrocytes, with large nuclei and long processes also stained positively for CXCR2 (Figure 8D). Similar results were obtained by immunofluorescence with both oligodendrocytes and astrocytes labeling positively for CXCR2 (data not shown). Double immunofluorescence was performed to identify the cell types expressing CXCR2. Results demonstrated that some CXCR2 co-localized with the oligodendroglial cell
Thus, CXCL1 overproduced by astrocytes in double-Tg occurred alongside receptors on both oligodendrocytes and astrocytes, was capable of initiating downstream effects in both these cell types (see below).

To determine whether CXCL1 production by astrocytes induced proliferation of oligodendrocytes during the course of EAE, BrdU was introduced into mice during doxycycline administration and incorporation was analyzed in spinal cord tissue. During the acute phase, BrdU was present in nuclei around inflammatory cuffs and was dispersed within white matter parenchyma of double-Tg animals (Figure 8, H and J). In contrast, BrdU was mainly found within inflammatory infiltrates in control mice, with limited uptake present in white matter regions (Figure 8, I and K). These results lend strength to the suggestion that CXCL1/CXCR2 interactions result in proliferation of cells within CNS white matter, which might explain the apparent increase in oligodendrocytes observed in the spinal cord and optic nerve in toluidine blue-stained sections of double-Tg animals (Figure 6, D and G).

**Discussion**

To further elucidate the role of chemokine receptors on human oligodendrocytes, and the role they might play during the course of MS, we generated and used a novel Tg mouse model in which CXCL1 expression was specifically induced within the CNS, under the control of the GFAP promoter. Analysis of spinal cord tissue from doxycycline-treated disease-free and EAE mice revealed an increase in $\beta$-gal expression in double-Tg mice but not in control single-Tg and wild-type animals. The increase in reporter gene product appeared to correlate with an increase in CXCL1 in astrocytes. CXCL1 binds to the chemokine receptor, CXCR2, which was found on mouse oligodendrocytes and some astrocytes in the same tissue. CXCR2-positive oligodendrocytes also expressed the oligodendrocyte lineage marker, Olig2.54 We recently reported the presence of CXC chemokine receptors (CXCR1, CXCR2, and CXCR3) on human oligodendrocytes, and the corresponding ligands, CXCL8, CXCL1, and CXCL10, on hypertrophic astrocytes (seen primarily...
Similar to our earlier results in human tissue, findings from the current study suggest that CXCL1/CXCR2-mediated signals might influence oligodendrocyte behavior during the course of inflammation in the CNS.

Double-Tg, CXCL1, or GFAP single-Tg and wild-type littermate mice all developed EAE when sensitized with MOG35-55 peptide, indicating that the two transgenes did not affect disease susceptibility. However, with the present novel Tg system, we could induce more CXCL1 production by astrocytes in double-Tg mice, demonstrated by the more increased intensity and widespread expression of the chemokine, compared with single-Tg controls, suggesting induced overproduction after doxycycline treatment. Staining of similar sections in mice with chronic EAE revealed diminished CXCL1 reactivity on astrocytes in double-Tg animals. Frozen sections from double-Tg mice were also stained for CXCR2, the receptor for CXCL1. Cells with typical oligodendroglial morphology were observed expressing CXCR2 (arrowheads) in spinal cord anterior columns. Astrocytes, with large nuclei and long processes (arrows), also stained positively for CXCR2. Double-immunofluorescence for CXCR2 (E, green) and Olig2 (F, red), demonstrated that CXCR2 was present on cells expressing the oligodendrocyte lineage marker (G, merge). To detect proliferation, BrdU was given to mice during doxycycline treatment and incorporation was analyzed in spinal cord sections. At 15 days after injection, BrdU was present in nuclei around inflammatory cuffs and was dispersed within white matter parenchyma of double-Tg mice. In contrast, BrdU was mainly found within cuffs in single-Tg mice, with limited BrdU uptake present in white matter regions. Immunofluorescence demonstrated the same pattern of staining with BrdU (red), staining more widespread in spinal cord parenchyma of double-Tg mice suggestive of oligodendrocyte proliferation (J), but more confined to inflammatory cuffs in single-Tg mice (K). Dotted lines in H–K outline the edge of spinal cord, and gray-white matter junction. Scale bars: 110 μm (A–C); 75 μm (D); 35 μm (E–G); 110 μm (H, I); 215 μm (J, K).
Using the pTRE2-N51/CXCL1 mouse strain, Wiekowski and colleagues\(^6\)\(^1\) studied the effect of CXCL1 overexpression on the migration of neutrophils. They found that systemic overproduction of the chemoattractant results in receptor desensitization and consequently reduced neutrophil migration. A similar mechanism might explain the observed increase in neutrophil infiltration within the CNS immediately after doxycycline treatment, followed by reduced inflammation. CXCL1 has been detected in spinal cords of Theiler’s murine encephalomyelitis virus (TMEV)-infected SJL/J mice at the onset of clinical signs and has been proposed to act as a chemoattractant of neutrophils and macrophages in these mice.\(^6\)\(^6\) A recent study by Carlson and colleagues\(^6\)\(^7\) further supports a role of the chemokine CXCL1 in the recruitment of polymorphonuclear cells into the CNS. The authors demonstrate that disruption of the CXCL1/CXCR2 pathway during development and relapse of EAE prevents blood-brain barrier breakdown, CNS leukocyte infiltration, and diminishes clinical signs of the disease.\(^5\)\(^7\) In our study, neutrophils, known to influence the development on EAE,\(^5\)\(^2\)\(^,\)\(^5\)\(^8\)\(^,\)\(^6\)\(^8\) might have become desensitized to subsequent stimulation by chemokines (CXCL1), thus minimizing the extent of inflammation in double-Tg animals. In contrast, inflammatory infiltrates were present late in the chronic phase of EAE in single-Tg (CXCL1 or GFAP) and wild-type mice, which produced normal levels of CXCL1. Continued presence of CD4\(^+\) T cells and F4/80-expressing macrophages in control animals undoubtedly contributed to the ongoing pathology (demyelination, WD). Although the limited amount of inflammation in double-Tg mice might foster repair, ongoing pathology would probably prevent similar processes in the single-Tg and wild-type control animals. Although controlled CXCL1 overproduction might have beneficial effects during the course of EAE, unregulated overexpression of the same chemokine within the CNS has been shown to cause a neurodegenerative condition in mice.\(^5\)\(^9\) To what extent the improved outcome in the double-Tg group was related to a reduced inflammatory response or a direct neuroprotective effect remains to be elucidated.

Chemokines have been shown to influence inflammatory processes within the CNS. In particular, CCL2, CCL3, CCL5, and CXCL10 seem to play an important role in the recruitment of T cells and macrophages, acting via CCR2, CCR1, CCR5, and CXCR3, respectively.\(^1\)\(^-\)\(^9\) More recently, CXCL12 and CCL20 have been shown to attract immature dendritic cells to MS lesions,\(^1\)\(^2\) whereas CXCL13 appeared to direct B-cell recruitment into the CNS,\(^1\)\(^0\)\(^,\)\(^1\)\(^1\) and CXCL13-deficient mice have a mild, self-limiting form of EAE.\(^6\)\(^8\) In addition to a pro-inflammatory role, chemokines might also have regulatory effects within the CNS. Studies using CXCR3-deficient mice have demonstrated that CXC10/CXCR3 interactions reduce the severity of disease in mice with EAE.\(^6\)\(^1\)\(^,\)\(^6\)\(^2\) In addition, Ethroy and colleagues\(^6\)\(^3\) have reported that overproduction of the chemokine CCL2 in vivo down-regulates Th1 immune responses, resulting in mice with an attenuated form of EAE. Thus, our finding that double-Tg animals overproducing CXCL1 after administration of doxycycline display a milder course of MOG-EAE, compared with single-Tg and wild-type mice, is in line with the wide variety of effects that chemokines might have on CNS inflammation.

Our observation that CXCL1 overexpression in the presence of CNS inflammation might induce oligodendrocyte proliferation is in agreement with previous studies in rodents in which it was shown that immature CXCR2\(^+\) oligodendrocytes proliferated in response to CXCL1 (from astrocytes) in combination with PDGF-AA.\(^4\)\(^,\)\(^7\) Moreover, elevated levels of CXCL1 in the jimpy mutant correlated with increased proliferation of NG2\(^+\) oligodendrocyte progenitors.\(^6\)\(^4\) CXCL1 has also been shown to provide a migratory stop signal for oligodendrocyte precursor cells, thus influencing positioning of cells of the oligodendrocyte lineage during CNS development.\(^4\)\(^8\) Together with our earlier results that showed CXCR2\(^+\) oligodendrocytes closely associated with CXCL1\(^+\) hypertrophic astrocytes at the edge of MS lesions,\(^2\)\(^4\)\(^,\)\(^5\)\(^5\) the current findings suggest that CXCL1/CXCR2-mediated signals might lead to the accumulation or recruitment of oligodendrocytes at the lesion margin and potentially promote repair. However, the possibility also exists that the production of CXCL1 might prevent oligodendrocyte migration past the lesion edge, thus disrupting repair processes. Exploration of these pathways affords novel therapeutic avenues to enhance the limited remyelination typically seen in MS.

Acknowledgments
We thank Miriam Pakingan for expert technical assistance, and Drs. Stefanie Gaupp and Barbara Cannella for help with EAE experiments.

References

2. Balashov KE, Rottman JB, Weiner HL, Hancock WW: CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 1999, 96:6873–6878
3. Tran EH, Kuziel WA, Owens T: Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1alpha or its CCR5 receptor. Eur J Immunol 2000, 30:1410–1415


